UA-45667900-1
Showing posts with label CRMP2. Show all posts
Showing posts with label CRMP2. Show all posts

Friday, 20 November 2026

MARA autism: could maternal antibodies account for a sizeable subgroup of autism diagnoses?



Could maternal antibodies account for as much autism as all known single-gene conditions combined?

That is the striking possibility raised by research into maternal autoantibody-related autism (MARA). A prospective study found particular maternal antibody patterns in about 10% of mothers of autistic children, compared with about 1% of controls. Some reviews estimate that recognised single-gene disorders account for roughly 5–10% of autism. The numbers sit in a similar range—but the antibody finding is an association, not yet a proven cause.

If even part of this signal proves causal, MARA could be one of the larger identifiable non-genetic subgroups of autism. That makes it worth taking seriously, while being careful not to claim more than the evidence shows.


Summary


  • Core hypothesis: MARA proposes that in some pregnancies, maternal IgG antibodies targeting fetal brain proteins cross the placenta and disrupt neurodevelopment.
  • Human and animal signal: Cohort studies have linked specific antibody combinations with autism—including blood collected during pregnancy—and animal models add biological plausibility.
  • Scale vs. causation: A 10% vs. 1% prospective difference points to a potentially meaningful subgroup, but association alone does not prove causation.
  • Commercial & recurrence limits: Claims about commercial testing (including a 20% prevalence figure and “over 97%” risk) and high recurrence risk outrun published, peer-reviewed data.
  • Prevention status: Folinic acid is a testable hypothesis from folate-receptor-antibody work, not a proven prenatal preventive treatment.


1. The commercial MAR-Autism test: what is being offered, and at what cost?

Before looking at the underlying science, it helps to be clear about the commercial test driving much of the current attention. MARAbio Systems—a Salt Lake City biotech company built around intellectual property licensed from Judy Van de Water’s laboratory at UC Davis—markets a maternal blood test called MAR-Autism across most of the United States through healthcare providers and a partnered telehealth option.

  • Who it is for: It is marketed to mothers who already have a child diagnosed with autism or showing early signs of autism. It is not validated for prenatal screening, and the company states it is not intended for use during pregnancy.
  • What it measures and claims: Using a maternal blood draw only (no sample is taken from the child), the assay looks for specific combinations of antibodies against eight fetal brain proteins. Company materials state that roughly 20% of mothers of autistic children carry these antibody patterns and claim an “over 97%” risk of autism diagnosis.
  • How those claims compare with published data: The 20% figure is roughly double the 10% rate seen in the prospective mid-pregnancy EMA study (and the 10% validation figure in CHARGE). Similarly, an “over 97%” risk figure is hard to reconcile with published cohort proportions (~1% of controls vs. ~10% of case mothers), as cohort prevalence alone does not establish positive predictive value in a real-world population.
  • Cost and coverage: MARAbio lists an upfront cash price of $640 , which covers the collection kit, shipping, maternal blood draw, and lab analysis. It is not covered by health insurance, though itemized receipts may be submitted for HSA/FSA reimbursement, and the company offers a 4-month payment plan and income-based financial assistance.

In short, families are being offered an out-of-pocket test marketed around “pre-symptom support” and “informed family planning,” backed by strong headline numbers. The sections below examine what the peer-reviewed studies actually show—and where the evidence stops.


2. What MARA proposes

During pregnancy, the placenta actively transports maternal IgG antibodies to the fetus via the neonatal Fc receptor (FcRn), normally providing passive immunity. The MARA hypothesis suggests that certain antibodies can also bind proteins in the developing brain and interfere with neurodevelopment.

This points to a maternal immune characteristic rather than necessarily a pathogenic variant in the child, though genetics may still shape antibody production or fetal susceptibility. Crucially, mothers do not cause these antibodies through anything they do: this is not a parenting or lifestyle failing.


3. The evidence, in layers

Layer 1: human association (discovery)

Researchers led by Judy Van de Water at UC Davis have focused on antibodies against eight proteins: CRMP1, CRMP2, GDA, LDHA, LDHB, NSE, STIP1, and YBOX.

Single-protein reactivity is common; the reported signal centres on specific combinations. In the 2021 CHARGE study (450 case mothers, 342 controls), notable patterns included:

  • CRMP1 + GDA: 4.2% of case mothers vs. 0% of controls (OR 31.04)
  • CRMP1 + CRMP2: 3.6% vs. 0% (OR 26.08)
  • NSE + STIP1: 3.1% vs. 0% (OR 22.82)

Because control rates were 0%, those odds ratios are statistically unstable, and blood was drawn two to five years after birth rather than during gestation. The study also linked maternal CRMP1 reactivity to higher autism severity scores (OR 2.3, 95% CI 1.36–3.99). Patterns appeared in up to 18% of the discovery sample and 10% of the validation sample—with the validation figure offering the more cautious benchmark.


Layer 2: a prospective test

A 2022 Early Markers for Autism (EMA) study analysed stored maternal blood collected at 15–20 weeks of gestation across 540 autism mothers, 184 mothers of children with intellectual disability without autism, and 420 general-population controls:

  • At least one pattern: 10.2% (autism) vs. 3.8% (intellectual disability) vs. 1.4% (controls)
  • Autism vs. controls: OR 7.81 (95% CI 3.32–22.43)
  • Autism vs. intellectual disability: OR 2.77 (95% CI 1.19–7.47), with no significant difference between intellectual disability and controls
  • Top pattern: CRMP1 + CRMP2 (~2.6% of case mothers vs. 0% of controls)

Gestational sampling makes this the strongest human dataset so far, though several caveats apply:

  • CRMP1 + GDA and NSE + STIP1 were not statistically significant here.
  • Over half of mothers across groups reacted to at least one single antigen; specificity depended on combinations.
  • Controls were not confirmed to be exclusively typically developing.
  • Patent holdings and commercial test development by the senior author make independent replication especially important.


CHARGE vs. EMA at a glance

Feature CHARGE Study (2021) EMA Study (2022)
Sampling timing 2–5 years after birth 15–20 weeks during pregnancy (prospective)
Sample size ~450 autism mothers; 342 controls 540 autism; 184 ID (without autism); 420 controls
Any target pattern Up to 18% (discovery) / 10% (validation) 10.2% (autism) vs. 3.8% (ID) vs. 1.4% (controls)
Overall odds ratio — OR 7.81 vs. controls (95% CI 3.32–22.43)
OR 2.77 vs. ID (95% CI 1.19–7.47)
Top specific patterns CRMP1 + GDA: 4.2% vs. 0% (OR 31.04)
CRMP1 + CRMP2: 3.6% vs. 0% (OR 26.08)
NSE + STIP1: 3.1% vs. 0% (OR 22.82)
CRMP1 + CRMP2: ~2.6% vs. 0% controls
(CRMP1 + GDA and NSE + STIP1 not significant)
Key limitations Post-natal blood draw; 0% controls make ORs statistically unstable Over half of mothers across all groups had single-antigen reactivity; control developmental status unconfirmed


Layer 3: animal experiments

Experimental models add mechanistic plausibility while remaining preliminary:

  • Non-human primates: Small rhesus-monkey studies using IgG from mothers of autistic children reported increased stereotypies and hyperactivity, with later work noting differences in brain growth and social development.
  • Rodents: Passive-transfer mouse and rat studies have reported behavioural shifts, including a 2025 rat study showing marked gene-expression changes after CRMP1 + CRMP2 exposure. An Oxford group separately found that maternal CASPR2 antibodies altered microglia and offspring behaviour in mice.

Small primate sample sizes, pooled or mixed antibody preparations, and overlapping research networks mean these findings support plausibility rather than proving human causation.

Layer 4: independent groups and dissent

Findings across independent teams are mixed:

  • Researchers at Hasselt University reported antibodies to a different four-protein panel in 16% of autism mothers vs. 4% of controls—supporting the broad concept without replicating the UC Davis eight-protein patterns.
  • An Oxford group linked maternal CASPR2 antibodies to intellectual disability rather than autism, saw no excess of NMDA-receptor antibodies, and concluded in a 2020 review that MARA likely accounts for a relatively small fraction of cases.

Broadly, multiple groups see evidence that maternal antibodies can influence fetal brain development, but the specific eight-protein patterns and their claimed subgroup size still require independent replication.


4. How common is it really?

Reported figures measure different things and shouldn't be treated as interchangeable:

  • CHARGE: up to 18% (discovery) and 10% (validation), measured years post-birth.
  • EMA: 10% vs. 1% during mid-pregnancy in one California cohort sampled in the early 2000s.
  • Company materials: around 20%.

Even with a ~9-percentage-point difference in EMA, observational association cannot be read directly as causal share without ruling out confounding and establishing causality. Still, comparing the ~10% prospective figure to rough 5–10% estimates for recognised single-gene conditions is useful as a scale benchmark—showing why MARA merits serious study if even part of the effect is causal, while leaving true population prevalence unknown.


5. Recurrence: the November 2026 announcement

In November 2026, MARAbio reported that CHARGE-linked antibody combinations also appeared in the MARBLES cohort and were associated with high recurrence in later-born siblings. Because the announcement did not publish sample sizes, recurrence percentages, confidence intervals, or peer-reviewed data, its predictive value cannot yet be verified.

In Baby Siblings Research Consortium data (2011 and 2024), baseline autism recurrence in younger siblings is already roughly 19–20%. For recurrence testing to add real clinical value, it must meaningfully outperform family history—something unpublished summary claims cannot yet demonstrate.


6. Folate receptor autoantibodies: the closest relative of MARA

Folate receptor alpha (FRα) autoantibodies operate through a different mechanism—potentially blocking folate transport across the choroid plexus into the brain and causing cerebral folate deficiency despite normal blood folate—but represent a closely watched neighbouring area. Because FRα antibodies also appear in some siblings and parents, they are not specific to autism.

In rats, gestational FRα-antibody exposure produced offspring behavioural changes that folinic acid reduced in one model. A 2021 review suggested studying folinic acid alongside standard folic acid in antibody-positive pregnancies, and EpiphanyASD has noted one clinician prescribing folinic acid to prospective parents who test positive—but controlled human pregnancy prevention trials do not exist.

Two distinct clinical questions are often conflated and need to stay separate:

  • Treating autistic children: In March 2026, the FDA approved leucovorin for cerebral folate transport deficiency due to a confirmed FOLR1 mutation—not for autism broadly, citing insufficient evidence of efficacy—while the largest randomised leucovorin trial in autistic children (Panda et al.) was retracted in January 2026, and the Child Neurology Society has stated that FRα-antibody status is not a validated predictor of treatment response.
  • Prenatal prevention: Whether maternal FRα antibodies affect fetal development and whether folinic acid can prevent that remains an open question for controlled research rather than an established prenatal practice.


7. Other prenatal mechanisms, and how they differ

  • Maternal immune activation (MIA): Animal models show that maternal infection or immune stimulation (involving signals such as IL-6 and IL-17A) can alter offspring development, though human infection and cytokine findings are mixed and MIA does not necessarily involve antibodies.
  • PANS and PANDAS: Proposed post-infectious, sudden-onset neuropsychiatric syndromes that can occur in autistic individuals, but differ from prenatal antibody transfer because they reflect post-natal immune processes and are not established autism subtypes.
  • Medication and environmental exposures: Valproate carries well-established gestational risk—a 2025 meta-analysis of eight cohorts (>6 million pregnancies) found an adjusted autism hazard ratio of 3.10, rising at higher doses—yet anyone taking valproate must consult their prescriber rather than stopping abruptly, given the serious risks of uncontrolled seizures. Other environmental exposures (air pollution, pesticides, metals) have more variable evidence.


8. Could these mechanisms interact?

Interactions between maternal antibodies and broader inflammation or metabolic factors are plausible, but early data remain tentative. A small EMA comparison (37 antibody-positive vs. 37 antibody-negative autism mothers) found higher interferon-gamma and a more inflammatory cytokine profile in the antibody-positive group, and an exploratory CHARGE analysis linked gestational diabetes with higher antibody prevalence in a severe-symptom subgroup (measured years post-pregnancy). None of these findings establishes direction of causality or explains individual pregnancies.


9. Can the risk be reduced?

Established standard care

  • Follow routine prenatal care: manage fever and infection, avoid alcohol, and review medications with a clinician before and during pregnancy.
  • Take standard prenatal folic acid.
  • Where clinically appropriate and guided by the prescribing doctor, avoid valproate during pregnancy.

These measures support general maternal and fetal health, though none is proven to prevent autism specifically.

Antibody-specific ideas (unproven / experimental)

  • Prenatal testing (unvalidated): Requires a test proven reliable for gestational use.
  • Broad antibody reduction (untested for MARA / non-selective): Plasmapheresis and IVIG are used in other antibody-mediated conditions, not validated here.
  • FcRn blockade (investigational / off-target to MARA): Agents like nipocalimab reduced maternal IgG in a small phase 2 trial for severe fetal haemolytic disease, showing technical feasibility rather than MARA suitability—and lowering maternal IgG carries potential trade-offs for newborn passive immunity.
  • Decoy/neutralising molecules (hypothetical): Early conceptual stage.
  • Targeting upstream triggers (preliminary): Cytokine and metabolic clues are too early to guide intervention.
  • Folinic acid for FRα antibodies (research hypothesis): Supported by rodent data, not controlled human pregnancy prevention trials.

None of these antibody-targeted approaches is ready for routine or self-directed use; pregnancy treatment choices belong with the pregnant individual and their clinical team.


10. What would settle the question

  • Independent, blinded replication of the eight-protein combinations in new cohorts.
  • Full peer-reviewed publication of CHARGE and MARBLES recurrence rates, denominators, and confidence intervals benchmarked against the 19–20% sibling baseline.
  • Longitudinal pre-pregnancy and across-pregnancy measurements to test pattern stability and true incremental predictive value over family history.
  • Direct studies linking maternal and cord-blood antibodies (including FRα) to developmental outcomes, followed by properly controlled trials before any preventive intervention is recommended.


Conclusion

MARA is a serious, testable hypothesis with a prospective human signal (10% vs. 1% in EMA) and animal data that make biological interference plausible. Its numerical scale is comparable enough to single-gene autism estimates to warrant careful investigation, yet association is not causation, replication and recurrence data remain incomplete, and prenatal interventions like folinic acid remain research questions rather than proven prevention.

Ultimately, MARA sits as one potential piece within a multifactorial landscape alongside genetics, other prenatal factors, and pathways still unknown.



For anyone wondering how much actual science underlies MARA autism here is an AI generated list of relevant references

Ramirez-Celis A, Becker M, Nuño M, Schauer J, Aghaeepour N, Van de Water J. Risk assessment analysis for maternal autoantibody-related autism (MAR-ASD): a subtype of autism. Mol Psychiatry. 2021;26:1551–1560. PMID 33483694. doi:10.1038/s41380-020-00998-8

Ramirez-Celis A, Croen LA, Yoshida CK, et al. Maternal autoantibody profiles as biomarkers for ASD and ASD with co-occurring intellectual disability. Mol Psychiatry. 2022;27:3760–3767. PMID 35618885. doi:10.1038/s41380-022-01633-4

Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology. 2008. PMID 18078998.

Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008;22:806–816.

Bauman MD, Iosif AM, Ashwood P, et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl Psychiatry. 2013;3:e278. doi:10.1038/tp.2013.47

Bruce MR, et al. Altered behavior, brain structure, and neurometabolites in a rat model of autism-specific maternal autoantibody exposure. Mol Psychiatry. 2023;28. PMID 36973347. doi:10.1038/s41380-023-02020-3

Gestational autoantibody exposure impacts early brain development in a rat model of MAR autism. Mol Psychiatry. 2025;30:3018–3028. doi:10.1038/s41380-025-02907-3

Marks K, Coutinho E, Vincent A. Maternal-autoantibody-related (MAR) autism: identifying neuronal antigens and approaching prospects for intervention. J Clin Med. 2020;9:2564. PMID 32784803. doi:10.3390/jcm9082564

Coutinho E, Jacobson L, Pedersen MG, et al. CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism. J Neurol Neurosurg Psychiatry. 2017;88:718.

Novel maternal autoantibodies in autism spectrum disorder: implications for screening and diagnosis (Hasselt University). Front Neurosci. 2023. PMID 36816132. doi:10.3389/fnins.2023.1067833

McLellan J, Croen L, Iosif AM, Yoshida C, Ashwood P, Yolken RH, Van de Water J. Altered cytokine and chemokine profile linked to autoantibody and pathogen reactivity in mothers of autistic children. Front Psychiatry. 2024;15:1348092. doi:10.3389/fpsyt.2024.1348092

Krakowiak P, Walker CK, Tancredi D, Hertz-Picciotto I, Van de Water J. Autism-specific maternal anti-fetal brain autoantibodies are associated with metabolic conditions. Autism Res. 2017;10(1):89–98. doi:10.1002/aur.1657. PMID 27312731.

MARAbio Systems. New clinical findings linking maternal autoantibodies to a non-genetic form of autism and high familial recurrence risk. Press release, 16 November 2026. Full recurrence data unpublished. Coverage: Contemporary Pediatrics, November 2026.

Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics. 2011;128:e488–e495. PMID 21844053. doi:10.1542/peds.2010-2825

Ozonoff S, et al. Familial recurrence of autism: updates from the Baby Siblings Research Consortium. Pediatrics. 2024;154(2). doi:10.1542/peds.2023-065297

Desai A, Sequeira JM, Quadros EV. Prevention of behavioral deficits in rats exposed to folate receptor antibodies: implication in autism. Mol Psychiatry. 2017;22:1291–1297. doi:10.1038/mp.2016.153

Moise KJ Jr, Ling LE, Oepkes D, et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med. 2024;391:526–537.

Brynge M, Gardner RM, Sjöqvist H, Lee BK, Dalman C, Karlsson H. Maternal levels of cytokines in early pregnancy and risk of autism spectrum disorders in offspring. Front Public Health. 2022;10:917563. doi:10.3389/fpubh.2022.917563